200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist
Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Shareholder votes
Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Annual Report to Security Holders
Changes in Board, Management or Compensation
Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence